Drug Discovery and Development covers strategies and technologies related to pharmaceutical research and development and drug formulation. GLP-1 revenue at Eli Lilly and Novo Nordisk, 2022-2025. Lilly’s tirzepatide franchise grew more than fivefold in three years while Novo’s semaglutide portfolio nearly tripled, pushing combined sales past $75B. Source: Eli Lilly 10-K, Novo Nordisk Annual Report 2025. Novo DKK→USD at IRS 2025 rate (6.617). Pfizer’s $43 billion Seagen acquisition became symbolic of its post-COVID spending spree. The acquisition gave the company an established oncology business and a deeper antibody-drug conjugate portfolio just as investors were grappling with the sharp decline of…
Pfizer’s $43 billion Seagen acquisition became symbolic of its post-COVID spending spree. The acquisition gave the company an established oncology business and a deeper antibody-drug conjugate portfolio just as investors were grappling with the sharp decline of its COVID vaccine and Paxlovid sales. Fast forward to today, and now Lilly is on its own buying…
The post Lilly’s plans to buy CAR-T firm Kelonia in deal worth up to $7 billion. Can its deal spree avoid Pfizer’s fate? appeared first on Drug Discovery and Development.
US Pharma Marketing